Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options... May 08
... Mar 05
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer.... Nov 02
-Advertisements-